bupropion

(redirected from Contrave)
Also found in: Dictionary, Wikipedia.

bupropion

 [bu-pro´pe-on]
a compound structurally similar to amphetamine, used in the form of the hydrochloride salt as an antidepressant and as an aid in smoking cessation to reduce the symptoms of nicotine withdrawal; administered orally.

bupropion

/bu·pro·pi·on/ (bu-pro´pe-on) a monocyclic compound structurally similar to amphetamine, used as the hydrochloride salt as an antidepressant and as an aid in smoking cessation.

bupropion

(byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

buPROPion

[boo͡prō′pē·on]
a heterocyclic mood-elevating drug used to treat some types of depression (trademark: Wellbutrin) and also to promote smoking cessation (trademark: Zyban).

bupropion

Zyban® Psychiatry An antidepressant Side effects Dry mouth, insomnia Contraindications Seizures, bulimia

bupropion

A drug used in the treatment of tobacco, drug and alcohol dependency. Bupropion reacts adversely with a wide range of other drugs and may induce seizures in sensitive persons. When used, a strict regime is necessary. A brand name is Zyban.

Bupropion

An antidepressant medication given to smokers for nicotine withdrawal symptoms. It is sold under the trade name Zyban.

bupropion (byōō´prō´pēon),

n brand names: Wellbutrin, Zyban;
drug class: antidepressant;
action: weak uptake inhibitor of dopamine, serotonin, norepinephrine; mechanism unknown;
uses: treatment of depression and anxiety disorders; tobacco cessation.
References in periodicals archive ?
In the coming year, we expect the overall market for anti-obesity medicines to grow significantly year over year and for Contrave to continue to gain overall market share.
Alarmingly, in addition to demonstrating only modest effectiveness, Contrave also proved to be unsafe during its clinical trials.
In a clinical trial involving patients without diabetes, those who took Contrave had an average weight loss of 4.
Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the company has submitted the Marketing Authorization Application (MAA) for Contrave to the European Medicines Agency (EMA) utilizing the EMA's Centralized Procedure.
Contrave combines two currently marketed drugs, naltrexone, used to reduce the urge to consume alcohol or addictive drugs, and bupropion, an antidepressant also used to combat smoking addiction.
This license agreement with GSK complements the IP foundation of Contrave, providing us with additional product formulation options as we pursue regulatory approval and potential commercialization of Contrave," said Michael Narachi, President and Chief Executive Officer, Orexigen Therapeutics.
Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel formulation of naltrexone SR in a single tri-layer tablet.
Contrave was developed by Orexigen to help to reduce appetite, increase metabolism and control cravings and over- eating behaviors.
When used as directed in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, Contrave provides another treatment option for chronic weight management for people who are obese or are overweight and have at least one weight-related health condition.
Understand the state of play with Orexigens Contrave
If approved, Kwang Dong will market and distribute Contrave as part of its distributorship agreement with Orexigen's wholly-owned subsidiary Orexigen Therapeutics Ireland Ltd.
Results from a study of Contrave in patients with mild to moderate obesity are expected soon, perhaps in early January.